US 7,524,822 B2
	Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments
Gerd Kraemer, Eberhardzell (Germany); Hans-Juergen Martin, Biberach (Germany); Gebhard Adelgoss, Biberach (Germany); Klaus Dugi, Dresden (Germany); Adil Duran, Biberach (Germany); Peter Eickelmann, Mittelbiberach (Germany); Steffen Maier, Biberach (Germany); Sabine Pinnetti, Biberach (Germany); Regine Ritter, Wiesbaden (Germany); Gebhard Schilcher, Mittelbiberach (Germany); Ruediger Streicher, Biberach (Germany); and Leo Thomas, Biberach (Germany)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim (Germany); and Ajinomoto Co., Inc., Tokyo (Japan)
Filed on Jan. 10, 2007, as Appl. No. 11/621,859.
Prior Publication US 2007/0244176 A1, Oct. 18, 2007
Int. Cl. A01N 43/04 (2006.01); A61K 31/70 (2006.01)

U.S. Cl. 514—27  [514/25; 536/4.1; 536/6.1; 536/6.2; 536/18.5]

10 Claims

1. Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside having an X-ray powder diffraction pattern that comprises peaks at 5.35, 10.76 and 16.20 degrees 2Θ (±0.1 degrees 2Θ), wherein said X-ray powder diffraction pattern is made using CuKα1 radiation.